Form 4: Enanta Pharmaceuticals Director Kristine Peterson Acquires Stock Options

Kristine Peterson, a director at Enanta Pharmaceuticals, acquired stock options exercisable for 15,700 shares of common stock on March 13, 2025.

Summary

• On March 13, 2025, Kristine Peterson, a director of Enanta Pharmaceuticals, acquired stock options to purchase 15,700 shares of the company's common stock.
• The exercise price of these options is $6.83 per share.
• The options vest monthly over one year, starting March 13, 2025, with the final installment vesting before the 2026 annual meeting of stockholders.
• The options expire on March 13, 2035.
• A Power of Attorney was filed, authorizing certain individuals to act on Peterson's behalf for SEC filings.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a transaction. The grant of options to a director is generally viewed as a slightly positive sign, indicating alignment of interests.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the vesting schedule of the options extends into the future.

Industry Context

This is a routine disclosure related to insider transactions, common in the pharmaceutical industry where stock options are frequently used as part of executive compensation packages.

Comparison to Industry Standards

• Stock option grants are a common component of compensation packages for directors and executives in the pharmaceutical industry.
• The vesting schedule and exercise price are typical for such grants, aligning the director's interests with those of the shareholders.

Key Dates